

Recent advancements in immunosuppressive therapies necessitated updates to the prevention and management guidelines for hepatitis B virus reactivation (HBVr). Published in Gastroenterology, these new recommendations focus on tailored risk management, antiviral prophylaxis, and monitoring strategies for patients at risk.
Understanding HBV Reactivation
HBVr occurs when HBV activity resurges due to suppressed immune defences. High-risk groups include those on immunosuppressive therapies, particularly B-cell-depleting agents. Notably, HBsAg-positive individuals face greater reactivation risks compared to those with resolved HBV infection.
Why Update Guidelines?
Since the American Gastroenterology Association’s (AGA) 2014 guidelines, immunosuppressive treatment options have expanded, including therapies like immune checkpoint inhibitors and CAR-T cell therapies. These updates reflect advancements, ensuring clinicians provide evidence-based care.
Key Recommendations
- Risk Stratification
Patients are categorized into low, moderate, or high-risk groups based on HBVr likelihood. Updated risk assessments incorporate drug exposures and patient preferences. - Antiviral Prophylaxis
- Strongly recommended for high-risk individuals.
- Start prophylaxis before risk-associated treatments and continue for 6-12 months post-treatment.
- Resistance-averse antivirals are emphasized.
- Monitoring for Low-Risk Patients
For those at low risk, periodic monitoring of HBV viral load and ALT levels (every 1-3 months) is recommended as an alternative to prophylaxis. - Universal Screening
Testing for HBsAg, anti-HBsAg, and anti-HBc is advised for all adults. Those with positive results should undergo HBV DNA testing to assess viral activity.
Practical Implications
The guidelines distinguish between strong and conditional recommendations, accommodating patient values, healthcare costs, and risk tolerance. This nuanced approach empowers clinicians and policymakers to balance preventive strategies with patient-specific needs.
Future Directions
Cost-effectiveness analyses and centralized databases for HBV serological results could further refine risk categorization, enhancing equitable care. These guidelines set a foundation for proactive HBVr management amidst evolving medical landscapes.
More Information: Ali, F. S., Nguyen, M. H., Hernaez, R., et al. (2025). AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals. Gastroenterology. doi:10.1053/j.gastro.2024.11.008.
more recommended stories
Air Pollution Hurts Brain Health in Just 4 Hours
Air Pollution Blurs the Mind, Impairs.
Brain Aging in Latin America Tied to Social, Health Gaps
Social and Health Disparities Drive Brain.
Surge in Non-Smokers Lung Cancer Tied to Pollution
Air Pollution Drives Lung Cancer Surge.
Autism Origins: Study Debunks Maternal Health Myths
A large-scale NYU Langone Health study.
Chemotherapy Side Effect: Chronic Nerve Pain in 40%
A recent global study published in.
Largest Cannabis Brain Study Finds Memory Impairment
New Study Reveals Cannabis’ Impact on.
How Long to Form a Habit? Study Reveals Surprising Insights
A recent systematic review published in.
Carnivore Diet-Induced Cholesterol Deposits Alarm Doctors
Man on High-Fat Carnivore Diet Develops.
Endometriosis: A Hidden Risk for Heart Disease
A recent study published in BMC.
Heart Failure Risk Cut Post-Attack with PR-364 Drug
Researchers at Cedars-Sinai Medical Center have.
Leave a Comment